Akari Therapeutics Plc Année d'introduction en bourse
Quel est le Année d'introduction en bourse de Akari Therapeutics Plc?
Le Année d'introduction en bourse de Akari Therapeutics Plc est 2013
Quelle est la définition de Année d'introduction en bourse?
Le premier appel public à l'épargne est un type d'offre publique dans lequel les actions d'une entreprise sont généralement vendues à des investisseurs institutionnels qui, pour leur part, vendent au grand public, pour la première fois, sur une bourse de valeurs.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
Année d'introduction en bourse des entreprises dans Health Care secteur sur NASDAQ par rapport à Akari Therapeutics Plc
Que fait Akari Therapeutics Plc?
akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.
Entreprises avec année d'introduction en bourse similaire à Akari Therapeutics Plc
- AMG Capital Trust II a Année d'introduction en bourse de 2012
- Live Nation Entertainment a Année d'introduction en bourse de 2012
- MGM Resorts International a Année d'introduction en bourse de 2012
- EnerSpar a Année d'introduction en bourse de 2012
- The Western Union a Année d'introduction en bourse de 2012
- Wameja a Année d'introduction en bourse de 2012
- Akari Therapeutics Plc a Année d'introduction en bourse de 2013
- Opus Bank a Année d'introduction en bourse de 2014
- Recro Pharma Inc a Année d'introduction en bourse de 2014
- Radius Recycling a Année d'introduction en bourse de 2014
- Progenity a Année d'introduction en bourse de 2014
- Axalta Coating Systems Ltd a Année d'introduction en bourse de 2014
- Anevia SA a Année d'introduction en bourse de 2014